Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On May 9, 2023, we reported on a study published in the Journal of the American Heart Association that examined the causal relevance of reproductive factors on cardiovascular disease (CVD) in women using a Mendelian randomization framework.
The study
Investigators first extracted uncorrelated, genome-wide significant single nucleotide polymorphisms from sex-specific genome-wide association studies of age at first birth, number of live births, age at menarche, and age at menopause. They then used inverse-variance weighted Mendelian randomization to evaluate outcomes of AF, CAD, HF, ischemic stroke, and stroke.
Results showed that earlier genetically predicted age at first birth increased the risk of CAD (odds ratio [OR] per year 1.49, 95% CI 1.28-1.74; P=3.72x10-7), HF (OR 1.27, 95% CI 1.06-1.53; P=.009), and stroke (OR 1.25, 95% CI 1.00-1.56; P=.048). Odds were partially mediated through BMI, T2D, blood pressure, and cholesterol traits.
Higher genetically predicted number of live births was associated with increased risk of AF (OR per increase in category of <2, 2, or >2 live births 2.91, 95% CI 1.16-7.29; P=.023), HF (OR 1.90, 95% CI 1.28-2.82; P=.001), ischemic stroke (OR 1.86, 95% CI 1.03–3.37; P=.039), and stroke (OR 2.07, 95% CI 1.22–3.52; P=.007). Earlier genetically predicted age at menarche was associated with an increased risk of CAD (OR per year 1.10, 95% CI 1.06-1.14; P=1.68x10-6) and HF (OR 1.12, 95% CI 1.07-1.17; P=5.06x10-7). Both associations were partially mediated by BMI, noted investigators.
Clinical implications
"The results support the emerging research focus on female‐specific risk factors, stressing the importance of their routine evaluation in clinical risk stratification. Additionally, the results highlight that close monitoring and early modification of cardiometabolic factors is a key strategy that will at least partly mitigate the increased cardiovascular risk conferred by these reproductive factors."
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.